Bone Biologics Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Bone Biologics Corporation on December 28, 2015. The filing details the adoption of a new Non-Employee Director Compensation Policy, amendments to director offer letters, and the approval of the 2015 Equity Incentive Plan by the Board of Directors and stockholders.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on corporate governance, equity compensation structures, and share issuance authorizations.
Material Changes and Equity Actions
- Director Compensation Policy: Approved on December 28, 2015. Non-employee directors (excluding the Board Chair) receive a $25,000 annual retainer; the Board Chair receives $35,000. Committee chairs receive an additional $5,000. Directors also receive annual stock options valued at $50,000, vesting quarterly over one year.
- 2015 Equity Incentive Plan: Approved by stockholders holding 71.77% of outstanding shares via unanimous written consent. The plan authorizes the issuance of up to 14,000,000 shares of Common Stock and includes an "evergreen" provision allowing annual increases of up to 5% of outstanding shares without further shareholder approval. The plan expires on December 27, 2025.
- Executive Option Grants: On December 28, 2015, the Board granted options to purchase 4,626,821 shares of Common Stock to executive officers at an exercise price of $1.59 per share.
- CEO Stephen R. La Neve: 2,081,191 shares.
- COO Jeffrey Frelick: 1,040,596 shares.
- CTO William J. Treat: 799,414 shares.
- CFO Deina Walsh: 705,620 shares (two separate grants).
- MTF Amendment: An agreement with the Musculoskeletal Transplant Foundation clarifies stock grant rights for Chairman Bruce Stroever, including a $50,000 value stock option vesting quarterly over one year.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosures regarding equity dilution inherent in the new incentive plan. The "evergreen" feature of the Equity Incentive Plan allows for potential future dilution of existing shareholders.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (32,211,956) to assess the dilution impact of the 14,000,000 share reserve and the 4,626,821 shares immediately granted to executives.
- Confirm the exercise price of $1.59 per share relative to the current market price of the stock.
- Review the vesting schedules for executive options, noting that some portions vested immediately upon grant.
- Monitor the "evergreen" provision which could increase the share reserve annually by up to 5% of outstanding shares.